The Wall Street Transcript: Investing in Biotech Companies with Free Cash Flow and Research Focus

View the Fund’s S.E.C standardized returns, rankings and other important disclosure information

"And these are out of favor, as the economy really looks strong, but we would argue there's still a lot of debt out there in the system, and these kinds of companies that generate enormous free cash flow and have strong leadership positions are a good value in today's market."